Trial Profile
An open label, phase 2 study of biweekly Velcade [bortezomib] and intermittent Caelyx [doxorubicin-liposomal] in patients with ovarian cancer failing platinum containing regimens
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Doxorubicin liposomal
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Takeda Oncology
- 15 Jul 2009 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 05 Oct 2008 Planned end date changed from 1 Sep 2008 to 1 Sep 2009 as reported by ClinicalTrials.gov.
- 15 Mar 2008 New trial record.